menu
    • menu
    [{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Cantor","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Bexicaserin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.23999999999999999,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Cantor","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Cantor"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"","graph1":null,"graph2":null,"graph3":"Longboard Pharmaceuticals","amount2":2.6000000000000001,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ H. Lundbeck AS","highestDevelopmentStatusID":null,"companyTruncated":"Longboard Pharmaceuticals \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Longboard Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bexicaserin","moa":"","graph1":null,"graph2":null,"graph3":"Longboard Pharmaceuticals","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Longboard Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Longboard Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Bexicaserin

    Menu

    Bexicaserin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longboard Pharmaceuticals Starts Phase 3 DEEp OCEAN Study

                            Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for the treatment of developmental & epileptic encephalopathies.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 12, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : H. Lundbeck AS

                            Deal Size : $2,600.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Denmark's Lundbeck Bets on Epilepsy Drug with $2.6 Bln Longboard Deal

                            Details : Lundbeck gains access to LP352 (bexicaserin), a novel 5-HT2C agonist in development for seizures associated with DEEs, including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : $2,600.0 million

                            October 14, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : H. Lundbeck AS

                            Deal Size : $2,600.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longboard Initiates Phase 3 DEEp SEA Study of Bexicaserin in Dravet Syndrome

                            Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for developmental & epileptic encephalopathies dravet syndrome.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 26, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longboard Receives Rare Pediatric and Orphan Drug Designations for Bexicaserin

                            Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for the treatment of Dravet syndrome.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 19, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longboard Pharmaceuticals Announces Positive Interim Results for Bexicaserin in DEEs

                            Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for the treatment of developmental & epileptic encephalopathies.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longboard Pharma Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

                            Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for the treatment of developmental & epileptic encephalopathies.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 01, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Longboard Pharmaceuticals: Positive Interim Results from PACIFIC Study on Bexicaserin

                            Details : LP352 (bexicaserin) is a potentially best-in-class & highly selective, oral, 5-HT2C receptor superagonist, which is being evaluated for the treatment of developmental & epileptic encephalopathies.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Cantor

                            Deal Size : $241.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Longboard Pharmaceuticals Announces Closing Of Public Offering Of Common Stock

                            Details : Proceeds will support R&D and clinical trial expenses for LP352, an oral 5-HT2C superagonist for treating seizures in DEEs, such as Dravet syndrome and Lennox-Gastaut syndrome.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Cantor

                            Deal Size : $241.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Cantor

                            Deal Size : $210.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

                            Details : Net proceeds will advance research and clinical trial expenses for LP352, an oral 5-HT2C superagonist for seizures in DEEs like Dravet and Lennox-Gastaut syndromes.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Cantor

                            Deal Size : $210.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Longboard Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Cantor

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

                            Details : Net proceeds will advance research and clinical trial expenses for LP352, an oral 5-HT2C superagonist for seizures in DEEs like Dravet and Lennox-Gastaut syndromes.

                            Brand Name : LP352

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 02, 2024

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Cantor

                            Deal Size : $172.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth